Osteosarcoma
The commonest bone cancer in teenagers; relapsed and metastatic disease remain hard to treat.
Registry changes (new trials, status, phase, endpoint and readout-date changes, results) come from the OncoSignal store, last verified against ClinicalTrials.gov 2026-11-11 08:26 UTC.
- Results postedResults posted: CabOSTar (NCT06341712)
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
- PaperEfficacy and safety of risvutatug rezetecan versus gemcitabine plus docetaxel in relapsed/refractory advanced osteosarcoma: Primary results from the ARTEMIS-011 phase 3 trial.
Xie L, Yao W, Hua Y et al. Annals of oncology : official journal of the European Society for Medical Oncology.
- PaperComparable efficacy of extraoral and intraoral photobiomodulation in preventing oral mucositis during high-dose methotrexate therapy in pediatric oncology: A single-blind randomized controlled trial.
Freitas IOP, Schuartz I, Renz GLK et al. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.
- Readout dueReadout due: NCT06521567 reached primary completion
GlaxoSmithKline. A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
- New trialNew Ph3 trial: FOSTER (NCT07871864)
Gustave Roussy, Cancer Campus, Grand Paris. Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
- PaperTriptolide as a multi-target anticancer agent: molecular mechanisms and translational potential.
Shadin M, Shakil Hossain M, Mandal S et al. Naunyn-Schmiedeberg's archives of pharmacology.
- Readout dueReadout due: NCT05642455 reached primary completion
USWM CT, LLC. SPEARHEAD-3 Pediatric Study
- PaperSwitch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial.
Bwakura-Dangarembizi M, Chappell E, Kityo C et al. Lancet (London, England).
- PaperAssessing the effect of chemotherapy dose reductions and time delay on event-free survival in Ewing Sarcoma: A retrospective analysis of the Euro Ewing 2012 trial.
Liu Y, Fiocco M, Kirton L et al. European journal of cancer (Oxford, England : 1990).
- Readout dueReadout due: SARCOME13 reached primary completion
UNICANCER. Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients
- Readout dueReadout due: NCT07142863 reached primary completion
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients
- Readout dueReadout due: REGOMAIN reached primary completion
Centre Leon Berard. Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
A phase advance is an asset's first trial at a higher phase than any earlier trial of the same asset in this indication. Readout due means the registry's primary completion date has passed; it is not a disclosure.